News related to Tarceva (Erlotinib) and/or conditions it is approved for
Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival As A First-Line Maintenance Therapy For Advanced Non-Small Cell Lung Cancer
Source: Lung Cancer News From Medical News Today [2008.11.08]
Genentech, Inc., (NYSE: DNA) and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva® (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo.
Tarceva Brings New Hope To Patients With Advanced Non Small Cell Lung Cancer
Source: Lung Cancer News From Medical News Today [2008.11.08]
Roche announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression free survival. The study showed that Tarceva (erlotinib), when given in first line maintenance - immediately following initial treatment with platinum-based chemotherapy - , significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse. Trial investigator, Prof. F.
Study Showed Tarceva Improved Progression-Free Survival As A First-Line Maintenance Therapy For Advanced Non-Small Cell Lung Cancer
Source: Lung Cancer News From Medical News Today [2008.11.07]
Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a global Phase III study (SATURN) met its primary endpoint and showed Tarceva® (erlotinib) significantly extended the time patients with advanced non-small cell lung cancer (NSCLC) lived without their cancer getting worse when given immediately following initial treatment with platinum-based chemotherapy, compared to placebo.
CTS: Sequential Erlotinib Therapy Influences Progression-Free Survival in NSCLC
Source: MedPage Today Hematology/Oncology [2008.11.19]
CHICAGO (MedPage Today) -- Progression-free survival among non-small-cell lung cancer patients improved if they were treated with erlotinib (Tarceva) in a sequential treatment strategy as opposed to use of the tyrosine kinase inhibitor as a second-line therapy.
CTS: Erlotinib Equally Effective Alone or in Combination Against Lung Cancer
Source: MedPage Today Hematology/Oncology [2008.11.18]
CHICAGO (MedPage Today) -- There were no differences in overall survival between non-small-cell lung cancer patients treated with erlotinib (Tarceva) alone or in combination with standard chemotherapy, researchers found.
CTS: Still Unclear Why Part of Drug Duo Greater than Sum in NSCLC
Source: MedPage Today Public Health & Policy [2008.11.14]
CHICAGO (MedPage Today) -- Oncologists are still trying to figure out why the one-two combination of bevacizumab (Avastin) and erlotinib (Tarceva) leads to a punchless overall survival benefit in non-small-cell lung cancer.
|
